Panacea Biotec Ltd.

₹325.15

-16.4 (-4.8%)

PANACEABIO Share Price

Pharmaceuticals & Biotechnology

As on March 13, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 1,993 Cr

P/E Ratio-237.94

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	340.38	Bearish
10-DMA	332.09	Bearish
20-DMA	338.35	Bearish
50-DMA	361.75	Bearish
100-DMA	372.43	Bearish
200-DMA	399.99	Bearish

Historical Performance

1 Year

-17.6%

3 Years

168.5%

5 Years

70.4%

10 Years

237.6%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	5,591	5,592	4,599	6,612	6,248
Total Expenditure	5,850	5,792	5,579	6,744	5,482
Other Income	207	258	517	110	100
Operating Profit	-53	57	-463	-22	866
Interest	39	36	44	1,808	1,853
Depreciation	348	367	391	438	456
Profit Before Tax	-79	15	128	14,494	-1,442
Consolidated Net Profit	-84	-12	-332	10,783	-1,477
Adjusted EPS	-1	---	-5	176	-24

Compounded Sales Growth

10 Years:-3.1

5 Years:0.5

3 Years:-3.3

TTM:0

Compounded Profit Growth

10 Years:-14.5

5 Years:-46.7

3 Years:-69.4

TTM:48.1

Stock Price CAGR

10 Years:13

5 Years:12

3 Years:41.3

TTM:-17.6

Return on Equity

10 Years:-3

5 Years:-24.1

3 Years:-5.4

last year:-1.4

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	61	61	61	61	61
Total Reserves	8,287	8,359	8,375	8,705	-2,348
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	1,036	2,651	2,707	851	9,600
Other Current Liabilities	1,049	1,276	1,157	5,030	1,872
Short Term Borrowings	---	---	---	---	---
Total Liabilities	13,012	14,123	14,426	17,351	11,774
Capital Work in Progress	935	747	280	49	212
Long Term Loans & Advances	580	2,424	2,282	215	176
Currents Investments	32	404	134	50	---
Short Term Loans and Advances	1,329	758	523	592	637
Total Current Assets	5,452	4,855	5,623	9,506	4,742
Total Assets	13,012	14,123	14,426	17,351	11,774
Adjusted Book Value	136	137	138	143	-37

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a low PE of -237.94, which may indicate undervaluation or subdued growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 41.3%, indicating sustained price appreciation.
The stock carries a beta of 0.9, indicating volatility broadly in line with the market.
In the last financial year, the company reported a negative or negligible EBITDA of ₹-53 million, indicating weak operating profitability.
In the previous financial year, the company generated revenue of ₹5591 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 830099.6

No. of Shares: 2553 (Approx)

Performance:-17%

P/L: ₹-169900.4

NIFTY Performance: 3.4%

1 day Top Gainers